Quick Takeaways Why It Matters? A new proprietary CNS asset from Orion, exclusively commercialized by Zoetis in the US, that taps into fast‑growing demand for medical management of canine anxiety and should expand the addressable market beyond situational noise phobia toward mo...
Quick Takeaways: Why It Matters? nixiFLOR gives vets and producers a lower‑cost, first‑generic alternative to Resflor Gold with the same florfenicol–flunixin combo and FDA‑confirmed bioequivalence for BRD treatment and BRD‑associated fever in beef and non‑l...
Quick Takeaways: Why It Matters? By extending Bravecto Quantum’s label to cover Asian longhorned and Gulf Coast ticks for a full 12 months, Merck further differentiates the product as the longest‑lasting, broadest‑spectrum injectable parasiticide available exclusively...
Quick Takeaways Why It Matters? Merck Animal Health strengthens its dermatology franchise with a differentiated, second-generation JAK inhibitor positioned as a convenient, first-line option for allergic pruritus. Once-daily dosing and rapid onset are likely to ...
Quick Takeaways: Why It Matters? Full approval elevates KBroVet from a conditional option to the reference standard for potassium bromide in canine idiopathic epilepsy, giving vets greater confidence in its long‑term use. Its once‑daily, chewable, liver...
Quick Takeaways: Why It Matters? Full approval and label expansion make Vetmedin the standard of care for early-stage MMVD, locking in pimobendan as the only FDA‑approved option for delaying CHF in Stage B2 dogs and driving guideline‑aligned, earli...
Dechra Secures FDA Approval for Zygolide (Pergolide) in Equine Pituitary Pars Intermedia Dysfunction
Quick Takeaways: Why It Matters? Zygolide gives vets and owners a lower-cost, FDA-approved alternative for managing PPID, which should improve treatment uptake in senior horses. The focus on flexible dosing and palatability makes long-term therapy more practical in th...
